TAVR (Transcatheter Aortic Valve Replacement): A Cardiologist's Guide to the Procedure, Recovery, and Outcomes

Transcatheter aortic valve replacement (TAVR) is the most consequential change in cardiac care in the past 15 years. A procedure that used to require splitting the breastbone, stopping the heart, and connecting the patient to a heart-lung bypass machine is now routinely done through a small puncture in the groin, with the patient lightly sedated, and most patients home the next morning. In my Encinitas practice, TAVR has fundamentally changed the conversation I have with patients facing severe aortic stenosis. This guide walks through what TAVR is, who it is for, who is still better served by surgery, and what to expect from the procedure and recovery.

What Is TAVR Treating?

TAVR treats severe aortic stenosis, a progressive narrowing of the aortic valve that restricts blood flow out of the heart. Once symptoms develop (exertional dyspnea, chest pain, or syncope), the natural history without valve replacement is poor, roughly 50% mortality within two years.

The aortic valve is the one-way door between the left ventricle and the aorta. With every heartbeat, the valve opens to let blood out to the body and closes tightly to prevent backflow. In aortic stenosis, the leaflets calcify, stiffen, and the valve opening shrinks. The left ventricle has to generate more and more pressure to push the same volume of blood through a smaller orifice. Over decades, the muscle thickens (concentric hypertrophy), and the patient compensates without symptoms.

The natural history shifts dramatically once symptoms appear. The classic triad is exertional dyspnea, exertional chest pain (angina), and syncope or near-syncope with exertion. Each of these signals that the heart can no longer compensate. Survival without valve replacement after symptom onset is roughly 2 years for syncope, 3 years for angina, and 2 years for heart failure. These numbers have been stable in the cardiology literature for decades.

The good news is that the disease is fixable. Once the valve is replaced, the left ventricle reverse-remodels, exercise tolerance returns, and symptoms resolve in most patients within weeks. The decision is no longer whether to replace the valve when severe symptomatic aortic stenosis is present; the decision is which type of replacement, surgical or transcatheter.

How Does TAVR Actually Work?

A catheter carrying a folded bioprosthetic valve is threaded from an artery (most commonly the femoral artery in the groin) to the diseased aortic valve. The new valve is then deployed inside the old one using either a balloon (Edwards SAPIEN) or a self-expanding nitinol frame (Medtronic Evolut, Boston Scientific ACURATE neo2). The new valve immediately takes over.

TAVR is an in-place valve replacement. The diseased valve stays where it is; the new valve is deployed inside it, displacing the calcified leaflets to the side. The native valve becomes the framework that holds the new valve in position.

Access in roughly 95% of cases is transfemoral, through a small puncture in the femoral artery at the top of the leg. A catheter delivery system is advanced retrograde through the aorta to the aortic valve, the new valve is positioned across the diseased valve under fluoroscopic and transesophageal echocardiographic guidance, and it is deployed.

The two dominant device families differ in deployment mechanism. The Edwards SAPIEN family (S3, S3 Ultra, current generation S4) is balloon-expandable. A balloon at the tip of the delivery catheter expands the new valve into position. The Medtronic Evolut family (Evolut Pro+, Evolut FX, current generation Evolut FX+) is self-expanding. A nitinol frame springs back into shape as the delivery sheath is retracted. A third option, the Boston Scientific ACURATE neo2, is also self-expanding with mechanical positioning aids. All three are in routine clinical use, and the choice between them is driven by patient anatomy and operator preference rather than clear superiority of one design.

The procedure itself takes 45 to 90 minutes. Most centers now perform TAVR under conscious sedation. The patient is comfortable but breathing on their own, with no intubation. General anesthesia is reserved for selected anatomical situations or when transesophageal echocardiographic guidance requires it.

This is dramatically different from surgical aortic valve replacement (SAVR), which requires median sternotomy, cardiopulmonary bypass, and a stopped heart. SAVR is a mature, excellent operation when performed by experienced surgeons, but it is open-heart surgery. Recovery from SAVR is measured in months; recovery from TAVR is measured in weeks.

What Does TAVR Day Look Like?

Most TAVR procedures take 45 to 90 minutes, are performed under light sedation rather than general anesthesia, and require one overnight hospital stay. Many patients walk later the same day and go home the next morning.

The day starts with a standard pre-procedure routine: fasting since midnight, IV placement, a small shave at the groin access site, and a final pre-procedure review. The team includes an interventional cardiologist, a cardiac surgeon (always available, sometimes scrubbed in), an imaging cardiologist running the echo, anesthesia, and the cath lab team.

In the procedure room, the patient lies flat on the table under a biplane fluoroscopy system. The groin is numbed with local anesthetic. Conscious sedation is administered, the patient is comfortable, drowsy, and may or may not remember the procedure. A catheter is advanced through the femoral artery, across the aortic arch, and to the aortic valve. The new valve is positioned with precision, and deployed. Brief pressure may be felt in the chest as the valve seats. The whole valve-deployment sequence takes a few minutes; the rest of the procedure is access, positioning, and closure.

At the end, the groin puncture is closed, usually with a closure device rather than surgical stitches. The patient is moved to a recovery area and lies flat for a few hours to allow the femoral artery to seal. A temporary pacing wire is typically placed during the procedure and removed shortly after if the heart’s electrical system behaves normally.

Most centers discharge the patient the next morning. Some stay an extra night if a permanent pacemaker was required (about 10 to 15% of TAVR patients need one, mostly with the Evolut device, related to the proximity of the conduction system to the aortic valve annulus). The typical hospital stay for modern transfemoral TAVR is 1 to 2 days, a dramatic change from the 5 to 7 days standard for SAVR a decade ago.

Discharge medications typically include a baby aspirin and either clopidogrel for 1 to 6 months or, if the patient has atrial fibrillation, their existing anticoagulation continued. Lifelong DOAC or warfarin is not required after routine TAVR unless the patient has another indication.

Who Is Eligible for TAVR?

TAVR is FDA-approved for adults of any surgical-risk category with severe symptomatic aortic stenosis. It is also approved for valve-in-valve treatment of failed surgical bioprosthetic valves and, more recently, for selected severe aortic regurgitation. The choice between TAVR and SAVR is shaped by age, anatomy, and patient preference.

TAVR vs Surgical Aortic Valve Replacement

The FDA approval history of TAVR has moved progressively from sicker patients to healthier patients, following the trial evidence. In 2011, PARTNER 1B established TAVR as superior to medical therapy in inoperable patients. In 2012, PARTNER 1A established TAVR as non-inferior to surgery in high-risk patients. PARTNER 2A and SURTAVI (2016 to 2017) extended the approval to intermediate-risk patients. PARTNER 3 and Evolut Low Risk (2019) established TAVR as non-inferior or superior to surgery in low-surgical-risk patients, the largest practical group of aortic stenosis patients. NOTION-2 (2024) extended the evidence into patients age 75 and younger.

The five-year follow-up data from PARTNER 3 and Evolut Low Risk, published in 2023 to 2025, showed continued non-inferiority of TAVR to SAVR on survival, stroke, and reintervention. Valve durability at five years was equivalent.

The practical result of this evidence base is that TAVR is now the dominant aortic valve replacement strategy in the US. The STS/ACC TVT Registry reports that roughly two-thirds of all aortic valve replacements are now performed by catheter. A decade ago, that number was essentially zero.

Beyond severe symptomatic aortic stenosis, two other indications have grown. Valve-in-valve TAVR treats degenerated surgical bioprosthetic valves; a new TAVR valve is deployed inside the failed surgical valve, avoiding repeat sternotomy. This is now routine and is one of the reasons even relatively young patients can reasonably choose a bioprosthetic surgical valve at the first operation. Aortic regurgitation is a more recent indication; dedicated devices like the JenaValve Trilogy are designed specifically for pure aortic regurgitation, where the lack of native valve calcium makes deployment of standard TAVR devices technically challenging.

When Is Open-Heart Surgery Still Better Than TAVR?

Surgical aortic valve replacement remains preferred for younger patients (especially under 65) with low surgical risk, patients with certain bicuspid valve anatomies, patients needing concomitant coronary artery bypass grafting, and patients with active endocarditis. The longer durability track record of surgical valves matters more in patients with decades of life ahead.

The durability question is the most important driver. Surgical bioprosthetic valves have a track record measured in decades; typical durability is 15 to 20 years before structural valve degeneration becomes clinically significant. TAVR valves have excellent five-year data and increasingly reassuring ten-year data, but they have not been around as long. For a 55-year-old, the choice of first valve is partly a choice about what the second or third valve will look like 20 years later, and surgical bioprosthetic followed by valve-in-valve TAVR is a well-validated lifetime-management strategy.

Bicuspid aortic valve disease, present in roughly 1% of the population, often presents with severe aortic stenosis in the fifties and sixties (earlier than tricuspid stenosis). Bicuspid valves have asymmetric calcification, frequently associated aortic dilation, and a valve geometry that is more challenging for TAVR. Many bicuspid patients do well with TAVR, but a meaningful minority, particularly those with extensive asymmetric calcium or a dilated ascending aorta that needs replacement, are better served by surgery.

Concomitant coronary artery disease requiring revascularization is a clear surgical indication. If a patient needs coronary artery bypass grafting at the time of valve replacement, a combined operation in a single setting is cleaner than staged TAVR plus a separate PCI strategy. The same logic applies to coexisting mitral regurgitation requiring intervention.

Active infective endocarditis is a surgical indication. The infected tissue must be physically debrided, and no transcatheter approach can replicate that. After the infection is treated and the patient has recovered, future valve interventions can be transcatheter.

Hostile femoral access is the final practical reason to choose surgery. Severely diseased or small femoral arteries may not accommodate the TAVR delivery system. Alternative access routes (subclavian, transcaval, transapical) exist, but for some patients the cleanest approach is surgical.

What Does the Heart Team Do?

Every TAVR candidate is reviewed by a multidisciplinary heart team: interventional cardiologist, cardiac surgeon, imaging cardiologist, and often the referring cardiologist. The team reviews anatomy on cardiac CT, calculates surgical risk (STS or EuroSCORE), and discusses patient-specific factors before recommending an approach.

The heart-team model is not optional in modern valve care; it is required by the FDA approval and the CMS coverage criteria. The composition is straightforward. It includes an interventional cardiologist who performs TAVR, a cardiac surgeon who performs SAVR, an imaging cardiologist who reads the CT and echo studies, and often a general cardiologist, a nurse navigator, and, in selected cases, a geriatrician or other specialist.

The pre-procedure workup includes a confirmatory echocardiogram, a coronary angiogram (to identify obstructive coronary disease that may require concomitant treatment), and a cardiac CT scan that maps the aortic valve, root, and access vessels in fine detail. The CT measurements are what determine the valve size and confirm whether transfemoral access is feasible.

A frailty assessment is part of the workup at every well-functioning center. The FRAILTY-AVR study and subsequent work have shown that simple measures (gait speed, grip strength, nutritional status, 5-meter walk time, functional independence) predict outcomes after both TAVR and SAVR better than chronological age. The point is not to disqualify patients, it is to give an honest estimate of expected benefit.

The output of the heart-team review is a recommendation, but the final decision is the patient’s. In ambiguous cases (intermediate risk, bicuspid anatomy, longer life expectancy), the team presents the trade-offs and the patient chooses. The goal is shared decision-making with all the information on the table.

What Does TAVR Recovery Look Like?

Most TAVR patients walk the same day, go home within 1 to 2 days, and resume normal activities within 1 to 2 weeks. Driving is usually permitted after 5 to 7 days. Cardiac rehabilitation accelerates the return to full function and is covered by Medicare after valve replacement.

The first 24 to 48 hours after TAVR are spent in a step-down or telemetry unit for cardiac rhythm monitoring (the temporary pacing wire is removed once the heart’s electrical system has demonstrated stability). Most patients walk the evening of the procedure or the next morning. Discharge is typically the day after the procedure.

The main restrictions in the first week are around the access site. Heavy lifting (nothing over about 10 pounds), vigorous activity, and long drives are avoided to protect the femoral arteriotomy closure. Walking is encouraged from day one. Most patients are cleared to drive at about a week and back to normal activity within two weeks.

The return of symptoms is faster than patients expect. The breathlessness, exertional chest tightness, or lightheadedness that drove the referral often resolves within days, sometimes immediately as the obstruction across the valve is gone. What patients notice later, around weeks 3 to 6, is the return of stamina. Walking farther, gardening longer, sleep improvements. Spouses often notice the change before the patient does.

Cardiac rehabilitation is something I recommend to virtually every TAVR patient who is a reasonable candidate. Twelve weeks of supervised exercise and education improves exercise capacity, quality of life, and adherence to medical therapy. Medicare covers it after valve replacement, and the evidence supporting it is strong. Home-based and virtual cardiac rehab programs work too and are increasingly available.

How Long Does a TAVR Valve Last?

Current evidence shows modern TAVR valves last at least 8 to 10 years, with newer-generation devices expected to last longer. The PARTNER 3 and Evolut Low Risk five-year follow-up data showed durability comparable to surgical bioprosthetic valves. Younger patients may eventually need a valve-in-valve procedure; older patients typically will not.

TAVR valves are biological tissue (bovine or porcine pericardium) mounted on a metal frame. They degenerate the same way surgical bioprosthetic valves do, gradually, with leaflet thickening, calcification, or tearing over many years. They do not fail abruptly.

At one year, TAVR and SAVR valves perform indistinguishably. At five years (PARTNER 3 and Evolut Low Risk five-year follow-up), they are still indistinguishable on every measured outcome, survival, stroke, hospitalization, and reintervention. Structural valve deterioration rates are low and equivalent at five years. The randomized data through 5 years is the strongest direct comparison available, and it favors no specific device class.

Ten-year data is now beginning to arrive for the earlier TAVR cohorts. Registry follow-up from the NOTION trial (10-year follow-up published 2022) and others is so far reassuring, with rates of structural valve degeneration roughly comparable to surgical bioprostheses. We do not yet have 15- or 20-year data for TAVR, which is why durability remains a real consideration in younger patients.

In practice, the durability question scales with age. For a patient in their 80s, the valve will almost certainly outlast them. For a patient in their 70s, modern TAVR durability is more than adequate for the expected horizon. For a patient in their 60s, the question becomes part of the lifetime-management plan: TAVR now, with valve-in-valve later if needed; or SAVR now, with valve-in-valve TAVR later. Either is reasonable. For a patient in their 50s, surgical bioprosthetic followed by valve-in-valve TAVR is more commonly chosen, because it preserves the longest-track-record valve as the first deployment and uses the catheter option as the future fallback.

What Should You Ask Your Cardiologist About TAVR?

Ask: how severe is my aortic stenosis, what is my STS surgical risk score, am I a candidate for TAVR or SAVR or both, what valve type and size is recommended for my anatomy, what is the local center’s TAVR volume and outcomes, what does recovery look like, and what is the expected durability for someone my age?

A useful set of questions for the heart-team visit:

• Have I been evaluated by a multidisciplinary heart team, and what is their recommendation? If one cardiologist is steering toward one approach without a heart-team review, ask for one.
• What are the specific features of my anatomy that matter? Tricuspid or bicuspid valve, calcium distribution, femoral access quality, root dimensions. A good team can answer these in plain language.
• Given my age and overall health, how long do I need this valve to last, and how does that shape the choice between TAVR and SAVR? This is the durability conversation, it should happen explicitly.
• If I get TAVR, what is the plan if the valve needs to be redone later? If SAVR, what is the plan when the surgical valve eventually wears out?
• What is the local center’s volume and experience? Outcomes at high-volume TAVR centers (more than 100 procedures per year) are measurably better than at low-volume centers. Asking is reasonable.
• What is the expected risk of pacemaker, stroke, and major bleeding in my case specifically?
• Is cardiac rehabilitation built into the plan?

The right team will have direct answers to all of these.

TAVR: The Bottom Line

TAVR has fundamentally changed how we treat severe aortic stenosis. For most patients over 65 with symptomatic severe AS, TAVR is now the first-line option. Younger patients, certain bicuspid anatomies, patients needing concomitant coronary bypass, and patients with active endocarditis still favor surgical valve replacement. The decision should be made by a multidisciplinary heart team after a structured workup that includes a cardiac CT, coronary angiography, and a frailty assessment.

In my Encinitas practice, the conversation about severe aortic stenosis now ends with a much better answer than it did a decade ago. The fix is gentler, the recovery is faster, and the outcomes at modern high-volume centers are excellent. If you have severe aortic stenosis and are noticing exertional dyspnea, chest pain, or lightheadedness, do not wait, see a cardiologist who works with a heart-team-equipped center and let the team look at the whole picture.

Frequently Asked Questions About TAVR

How is TAVR different from open-heart surgery?

TAVR places a new valve through a catheter without opening the chest, stopping the heart, or using cardiopulmonary bypass. Surgical aortic valve replacement requires sternotomy, the heart-lung machine, and a stopped heart. Recovery from TAVR is days; recovery from open surgery is months.

How long does a TAVR procedure take?

The procedure takes 45 to 90 minutes. Most patients receive light sedation rather than general anesthesia. Total hospital stay is typically 1 to 2 days.

Will I be awake during TAVR?

Most TAVR procedures are now done under conscious sedation, you will be sleepy and comfortable but breathing on your own. Some patients receive general anesthesia depending on the access route.

How long does a TAVR valve last?

At least 8 to 10 years on current trial follow-up, with newer devices expected to last longer. The valve-in-valve option means a worn-out TAVR valve can later be replaced through another catheter procedure.

Can a TAVR valve be replaced if it wears out?

Yes. A valve-in-valve TAVR places a new device inside the failed first one. This is routine and is part of what makes TAVR appropriate even for younger patients.

Do I need blood thinners after TAVR?

Most patients take antiplatelet therapy (aspirin alone or with clopidogrel) for 1 to 6 months. Patients with atrial fibrillation continue their existing anticoagulation. Lifelong DOAC or warfarin is NOT required after routine TAVR.

What is the stroke risk during TAVR?

The 30-day stroke risk is approximately 2 to 3%, comparable to or lower than surgical valve replacement. Cerebral protection devices like the Sentinel filter capture debris during the procedure and may further reduce stroke risk in selected patients.

Can TAVR treat aortic regurgitation, not just stenosis?

Yes, in selected cases. Dedicated devices like the JenaValve Trilogy are being developed specifically for aortic regurgitation. Standard SAPIEN and Evolut devices are not approved for primary AR outside of valve-in-valve indications.

References

1. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. Circulation. 2021;143(5):e72-e227.

2. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal. 2022;43(7):561-632.

3. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients (PARTNER 3). New England Journal of Medicine. 2019;380(18):1695-1705.

4. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients (Evolut Low Risk). New England Journal of Medicine. 2019;380(18):1706-1715.

5. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years (PARTNER 3 five-year). New England Journal of Medicine. 2023;389(21):1949-1960.

6. Forrest JK, Deeb GM, Yakubov SJ, et al. 5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk five-year). Journal of the American College of Cardiology. 2025;85(15):1523-1532.

7. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients (PARTNER 2A). New England Journal of Medicine. 2016;374(17):1609-1620.

8. Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients (SURTAVI). New England Journal of Medicine. 2017;376(14):1321-1331.

9. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients (PARTNER 1A). New England Journal of Medicine. 2011;364(23):2187-2198.

10. Leon MB, Smith CR, Mack MJ, et al. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery (PARTNER 1B). New England Journal of Medicine. 2010;363(17):1597-1607.

11. Jørgensen TH, Thyregod HGH, Savontaus M, et al. Transcatheter versus surgical aortic valve replacement in patients ≤75 years old with symptomatic severe aortic stenosis (NOTION-2). European Heart Journal. 2024;45(37):3672-3683.

12. Carroll JD, Mack MJ, Vemulapalli S, et al. STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology. 2020;76(21):2492-2516.

13. Afilalo J, Lauck S, Kim DH, et al. Frailty in Older Adults Undergoing Aortic Valve Replacement (FRAILTY-AVR). Journal of the American College of Cardiology. 2017;70(6):689-700.

14. Blanke P, Weir-McCall JR, Achenbach S, et al. Computed Tomography Imaging in the Context of Transcatheter Aortic Valve Implantation/Replacement. JACC: Cardiovascular Imaging. 2019;12(1):1-24.

15. Makkar RR, Yoon SH, Leon MB, et al. Association Between Transcatheter Aortic Valve Replacement for Bicuspid vs Tricuspid Aortic Stenosis and Mortality or Stroke. JAMA. 2019;321(22):2193-2202.

16. Ribeiro RVP, Yanagawa B, Légaré JF, et al. Cardiac Rehabilitation After Transcatheter Aortic Valve Replacement. Canadian Journal of Cardiology. 2021;37(7):1074-1083.